Arvin Yang M.D., Ph.D.
Net Worth
Last updated:
What is Arvin Yang M.D., Ph.D. net worth?
The estimated net worth of Dr. Arvin Yang M.D., Ph.D. is at least $2,444,649 as of 17 Jan 2023. He owns shares worth $223,748 as insider, has earned $86,741 from insider trading and has received compensation worth at least $2,134,160 in Mersana Therapeutics, Inc..
What is the salary of Arvin Yang M.D., Ph.D.?
Dr. Arvin Yang M.D., Ph.D. salary is $533,540 per year as Senior Vice President & Chief Medical Officer in Mersana Therapeutics, Inc..
How old is Arvin Yang M.D., Ph.D.?
Dr. Arvin Yang M.D., Ph.D. is 49 years old, born in 1976.
What stocks does Arvin Yang M.D., Ph.D. currently own?
As insider, Dr. Arvin Yang M.D., Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Mersana Therapeutics, Inc. (MRSN) | Senior Vice President & Chief Medical Officer | 30,821 | $7.26 | $223,748 |
What does Mersana Therapeutics, Inc. do?
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Arvin Yang M.D., Ph.D. insider trading
Mersana Therapeutics, Inc.
Dr. Arvin Yang M.D., Ph.D. has made 3 insider trades between 2021-2023, according to the Form 4 filled with the SEC. Most recently he sold 2,209 units of MRSN stock worth $12,680 on 17 Jan 2023.
The largest trade he's ever made was exercising 18,500 units of MRSN stock on 30 Nov 2021. As of 17 Jan 2023 he still owns at least 30,821 units of MRSN stock.
Mersana Therapeutics key executives
Mersana Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Arvin Yang M.D., Ph.D. (49) Senior Vice President & Chief Medical Officer
- Dr. Timothy B. Lowinger (61) Chief Science & Technology Officer
- Mr. Brian C. DeSchuytner (47) Senior Vice President & Chief Financial Officer
- Ms. Anna Protopapas (61) Pres, Chief Executive Officer & Director